Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study

医学 内科学 放化疗 头颈部 肿瘤科 基底细胞 顺铂 头颈部癌 头颈部鳞状细胞癌 放射治疗 化疗 外科 总体生存率
作者
Xu-Shan Sun,Yungan Tao,Christophe Le Tourneau,Y. Pointreau,Christian Sire,Marie‐Christine Kaminsky,Alexandre Coutté,M. Alfonsi,Pierre Boisselier,Laurent Martin,J. Miroir,Jean‐François Ramée,Jean‐Pierre Delord,Florian Clatot,Frédéric Rolland,Julie Villa,Nicolas Magné,Olgun Eliçin,Elisabeta Gherga,F. Nguyen,C. Lafond,G. Béra,Valentin Calugaru,Lionnel Geoffrois,Bruno Chauffert,Angela Zubel,Claudio Zanna,S. Brienza,Philippa Crompton,Elisabeth Rouits,Kathrin Gollmer,Sergio Szyldergemajn,Jean Bourhis
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:21 (9): 1173-1187 被引量:100
标识
DOI:10.1016/s1470-2045(20)30327-2
摘要

Background Debio 1143 is an orally available antagonist of inhibitor of apoptosis proteins with the potential to enhance the antitumour activity of cisplatin and radiotherapy. The radiosensitising effect of Debio 1143 is mediated through caspase activation and TNF, IFNγ, CD8 T cell-dependent pathways. We aimed to investigate the efficacy and safety of Debio 1143 in combination with standard chemoradiotherapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck. Methods This double-blind, multicentre, randomised, phase 2 study by the French Head and Neck Radiotherapy Oncology Group (GORTEC) was run at 19 hospitals in France and Switzerland. Eligible patients were aged 18–75 years with locoregionally advanced, squamous cell carcinoma of the head and neck (characterised as non-metastatic, measurable stage III, IVa, or IVb [limited to T ≥2, N0–3, and M0] disease), Eastern Cooperative Oncology Group performance status of 0 or 1, a history of heavy tobacco smoking (>10 pack-years) with no previous or current treatment for invasive head and neck cancer, and no previous treatment with inhibitor of apoptosis protein antagonists. Patients were randomly assigned (1:1) to receive oral Debio 1143 (200 mg per day on days 1–14 of 21-day cycles, for three cycles) or oral placebo (20 mg/mL, administered at the same dosing schedule) using a stochastic minimisation technique according to node involvement and primary tumour site, and HPV-16 status in patients with an oropharyngeal primary tumour site. All patients received standard high-dose cisplatin chemoradiotherapy. The primary endpoint was the proportion of patients with locoregional control 18 months after chemoradiotherapy, analysed in the intention-to-treat population (primary analysis), and repeated in the per-protocol population. Responses were assessed according to Response Evaluation Criteria in Solid Tumors (version 1.1). This trial is registered with ClinicalTrials.gov, NCT02022098, and is still active but not recruiting. Findings Between Jan 25, 2016, and April 24, 2017, 48 patients were randomly assigned to the Debio 1143 group and 48 to the placebo group (one patient in the placebo group did not receive the study drug and was not included in the safety analysis). Median duration of follow-up was 25·0 months (IQR 19·6–29·4) in the Debio 1143 group and 24·2 months (6·6–26·8) in the placebo group. Locoregional control 18 months after chemoradiotherapy was achieved in 26 (54%; 95% CI 39–69) of 48 patients in the Debio 1143 group versus 16 (33%; 20–48) of 48 patients in the placebo group (odds ratio 2·69 [95% CI 1·13–6·42], p=0·026). Grade 3 or worse adverse events were reported in 41 (85%) of 48 patients in the Debio 1143 group and in 41 (87%) of 47 patients in the placebo group. The most common grade 3–4 adverse events were dysphagia (in 24 [50%] patients in the Debio 1143 group vs ten [21%] in the placebo group), mucositis (in 15 [31%] vs ten [21%]), and anaemia (in 17 [35%] vs 11 [23%]). Serious treatment-emergent adverse events were recorded in 30 (63%) of 48 patients in the Debio 1143 group and 28 (60%) of 47 in the placebo group. In the placebo group, two (4%) deaths were due to adverse events (one multiple organ failure and one asphyxia; neither was considered to be related to treatment). No deaths due to adverse events occurred in the Debio 1143 group. Interpretation To our knowledge, this is the first treatment regimen to achieve superior efficacy in this disease setting against a high-dose cisplatin chemoradiotherapy comparator in a randomised trial. These findings suggest that inhibition of inhibitor of apoptosis proteins is a novel and promising approach in this poor prognostic population and warrant confirmation in a phase 3 study with the aim of expanding the therapeutic options for these patients. Funding Debiopharm.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
追风筝的少女完成签到 ,获得积分10
2秒前
desperado完成签到 ,获得积分10
3秒前
舒心的青亦完成签到 ,获得积分10
5秒前
jf完成签到 ,获得积分10
6秒前
LIUJIE完成签到,获得积分10
7秒前
lrid完成签到 ,获得积分10
8秒前
8秒前
自觉语琴完成签到 ,获得积分10
9秒前
Jasmineyfz完成签到 ,获得积分10
17秒前
豆腐青菜雨完成签到 ,获得积分10
19秒前
21秒前
玖月完成签到 ,获得积分10
28秒前
28秒前
果冻完成签到 ,获得积分10
28秒前
王昭完成签到 ,获得积分10
28秒前
李想发布了新的文献求助10
33秒前
weinaonao完成签到,获得积分10
33秒前
伯爵完成签到 ,获得积分10
35秒前
wdccx完成签到,获得积分10
37秒前
carlin完成签到,获得积分10
38秒前
北城完成签到 ,获得积分10
44秒前
土豆晴完成签到 ,获得积分10
45秒前
卡戎529完成签到 ,获得积分10
46秒前
可耐的问柳完成签到 ,获得积分10
46秒前
liujinjin完成签到,获得积分10
52秒前
研友_西门孤晴完成签到,获得积分10
54秒前
planto完成签到,获得积分10
57秒前
wonwojo完成签到 ,获得积分10
57秒前
dslnfakjnij完成签到 ,获得积分10
57秒前
科研通AI2S应助btk采纳,获得30
59秒前
鲁卓林完成签到,获得积分10
1分钟前
Lee完成签到,获得积分20
1分钟前
无辜的行云完成签到 ,获得积分0
1分钟前
ran完成签到 ,获得积分10
1分钟前
行走De太阳花完成签到,获得积分10
1分钟前
Hindiii完成签到,获得积分10
1分钟前
火星上的雨柏完成签到,获得积分10
1分钟前
Shabby0-0完成签到,获得积分10
1分钟前
666完成签到 ,获得积分10
1分钟前
liu完成签到,获得积分10
1分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968578
求助须知:如何正确求助?哪些是违规求助? 3513391
关于积分的说明 11167428
捐赠科研通 3248822
什么是DOI,文献DOI怎么找? 1794499
邀请新用户注册赠送积分活动 875116
科研通“疑难数据库(出版商)”最低求助积分说明 804664